PharmaResearch Posts Record Q2 Earnings, Third Target Price Seen Higher
PharmaResearch posted record second-quarter results and surpassed 100 billion won in first-half revenue. Technically, the stock settled above the 240-day moving average and formed a golden cross, confirming further upside potential. Manager Kim Tae said, "For now, I think we can look at opening the upside a bit more," offering a positive outlook.


